-
-
-
-
-
-
-
TD Cowen on Black Diamond Therapeutics (BDTX) Amid 18% Drop: 'is unclear if the FDA will require Ph3 run-in or additional Ph2 dosing work extending competitor's lead'
-
-
-
-
-
-
-
Black Diamond Therapeutics' (BDTX) Phase 2 Silevertinib Data Encouraging - Stifel
-
-
-
-
-
-
-
Black Diamond Therapeutics, Inc. (BDTX) Tops Q1 EPS by 93c
-
-
-
-
-
-
-
NAYA Biosciences Announces Nomination of New Board Members
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)
-
-
-
-
-
-
-
Black Diamond Therapeutics, Inc. (BDTX) Tops Q2 EPS by 3c
-
-
446,429 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

